SARDH

Across TCGA pan-cancer cohorts, SARDH mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SARDH data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SARDH mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SARDH expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, UCEC, and PDAC are the cancer types where SARDH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	II,III,IV	0.926	0.675	.003	39	view →
UCEC	OS	Median	II,III,IV	0.638	1.000	.014	24	view →
PDAC	DFS	Median	All	0.265	0.442	.006	8	view →
CCRCC	OS	Median	IV	1.000	0.451	.016	7	view →
LSCC	DFS	Quartile	II,III,IV	0.353	0.812	.009	6	view →
LUAD	DFS	Tertile	All	0.847	0.420	.007	5	view →
GBM	DFS	Quartile	All	0.657	0.839	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SARDH–HNSC (DFS)

Open the HNSC breakdown →